AbCellera Biologics Inc. ABCL Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s contract liabilities?
- AbCellera Biologics Inc. (ABCL) reported contract liabilities of $8.99M in Q1 2026.
- How has AbCellera Biologics Inc.'s contract liabilities changed year-over-year?
- AbCellera Biologics Inc.'s contract liabilities decreased by 72.4% year-over-year, from $32.54M to $8.99M.
- What is the long-term trend for AbCellera Biologics Inc.'s contract liabilities?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s contract liabilities has grown at a -11.2% compound annual growth rate (CAGR), from $27.41M to $17.03M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.